Last reviewed · How we verify
NCT03552692
Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
Phase 2 trial testing Venetoclax in T-Cell Lymphoma Relapsed in 22 participants. Terminated before completion.
4 March 2020
Quick facts
| Lead sponsor | Fondazione Italiana Linfomi - ETS |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 25 September 2018 |
| Primary completion | 4 March 2020 |
| Estimated completion | 17 February 2023 |
| Sites | 13 locations across Italy |
Drugs / interventions tested
- Venetoclax (venetoclax) — full drug profile →
Conditions studied
- T-Cell Lymphoma Relapsed — all drugs for T-Cell Lymphoma Relapsed →
- T-Cell Lymphoma Refractory — all drugs for T-Cell Lymphoma Refractory →
Sponsor
Fondazione Italiana Linfomi - ETS — full company profile →
Who can join
18 and older, any sex, with T-Cell Lymphoma Relapsed or T-Cell Lymphoma Refractory. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The FIL\_VERT study is a phase II, open label, multicenter clinical trial. The primary of objective of the Study is to evaluate the efficacy of Venetoclax ABT-199/GDC-0199) in terms of overall response rate (ORR) in patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal T-cell lymphomas of T-follicular helper origin (TFH)
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Biomarker-driven management strategies for peripheral T cell lymphoma.
Mulvey E, Ruan J. · · 2020 · cited 29× · PMID 32448357 · DOI 10.1186/s13045-020-00889-z -
Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma.
Mohammed Saleh MF, Kotb A, Abdallah GEM, Muhsen IN, et al · · 2021 · cited 20× · PMID 34940095 · DOI 10.3390/curroncol28060456 -
Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine.
Zhang Y, Lee D, Brimer T, Hussaini M, et al · · 2020 · cited 11× · PMID 32637355 · DOI 10.3389/fonc.2020.00898 -
Updates in the Treatment of Peripheral T-Cell Lymphomas.
Saleh K, Michot JM, Ribrag V. · · 2021 · cited 10× · PMID 34188559 · DOI 10.2147/jep.s262344 -
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.
Ballotta L, Zinzani PL, Pileri S, Bruna R, et al · · 2021 · cited 9× · PMID 34938664 · DOI 10.3389/fonc.2021.789891 -
The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies.
Luo C, He S, Shi F, Zhou J, et al · · 2024 · cited 7× · PMID 39056714 · DOI 10.3390/biology13070521 -
Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL).
Du J, Jin S, Zhang M, Fu X, et al · · 2023 · cited 3× · PMID 37188182 · DOI 10.3389/fonc.2023.1163190 -
New Drug Development and Clinical Trial Design by Applying Genomic Information Management.
Ko YK, Gim JA. · · 2022 · cited 2× · PMID 35893795 · DOI 10.3390/pharmaceutics14081539
Verify or expand the search:
- PubMed search for NCT03552692
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Venetoclax
Trials testing the same drug.
- NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
- NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting
Other Fondazione Italiana Linfomi - ETS trials
Trials by the same sponsor.
- NCT07453095 — Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy · Phase 2 · not yet recruiting
- NCT07256158 — PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma · Phase 3 · not yet recruiting
- NCT07207785 — PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma · Phase 2 · not yet recruiting
- NCT06781359 — Study on Plasmablastic Lymphoma Patients · recruiting
- NCT06492837 — Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03552692 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione Italiana Linfomi - ETS
- Last refreshed: 12 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03552692.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing